Spasticity increases during pregabalin withdrawal

References

• Lance JW. Symposium synopsis. Spasticity: Disordered motor control, RG Feldman, RR Young, WP Koella. Year Book Medical Publishers. 1980; 485–494
   Google Scholar
• Pandyan AD, Gregoric M, Barnes MP, Wood D, Van Wijck F, Burridge J, Hermens H, Johnson GR. Spasticity: Clinical perceptions, neurological realities and meaningful measurement. Disability and Rehabilitation 2005; 27: 2–6
   PubMed Web of Science ®Google Scholar
• Esquenazi A, Mayer N. Botulinum toxin for the management of muscle overactivity and spasticity after stroke. Current Atherosclerosis Reports 2001; 3: 295–298
   PubMedGoogle Scholar
• Barnes MP. An overview of the clinical management of spasticity. An overview of the clinical management of spasticity2nd, MP Barnes, GR Johnson. Cambridge University Press, Cambridge 2008; 1–8
   Google Scholar
• Shakespeare DT, Boggild M, Young CA. Antispasticity agents for multiple sclerosis. Cochrane Database of Systematic Reviews 2003; 4, CD001332
   Google Scholar
• Grazko MA, Polo JB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms and rigidity. Neurology 1995; 45: 712–717
   PubMed Web of Science ®Google Scholar
• Brashear A, Gordon MF, Elovic E, Kassicieh VD, Mariniak C, Do M, Lee C, Jenkins S. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. New England Journal of Medicine 2002; 347: 395–400
   PubMed Web of Science ®Google Scholar
• McCrory P, Turner-Stokes L, Baguley IJ, De Graaff S, Katrak P, Sandanam J, Davies L, Munns M, Hughes A. Botulinum toxin A for treatment of upper limb spasticity following stroke: A multi-centre randomized placebo-controlled study of the effects on quality of life and other person centred outcomes. Journal of Rehabilitation Medicine 2009; 41: 536–544
   PubMed Web of Science ®Google Scholar
• Ivanhoe CB, Francisco GE, McGuire JR, Subramanian T, Grissom SI. Intrathecal Baclofen Management of poststroke spastic hypertonia: Implications for function and quality of life. Archives of Physical Medicine and Rehabilitation 2006; 87: 1509–1515
   PubMed Web of Science ®Google Scholar
• Baguley IJ, Bailey KM, Slewa-Younan S. Prolonged anti-spasticity effects of bolus intrathecal baclofen. Brain Injury 2005; 19: 545–548
   PubMed Web of Science ®Google Scholar
• Damiano DL, Alter KE, Chambers H. New clinical and research trends in lower extremity management for ambulatory children with cerebral palsy. Physical Medicine & Rehabilitation Clinics of North America. 2009; 20: 469–491
   PubMed Web of Science ®Google Scholar
• McLean MJ, Gidal BE. Gabapentin dosing in the treatment of epilepsy. Clinical Therapeutics 2003; 25: 1382–1406
   PubMed Web of Science ®Google Scholar
• Mueller ME, Gruenthal M, Olson WL, Olson WH. Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Archives of Physical Medicine and Rehabilitation 1997; 78: 521–524
   PubMed Web of Science ®Google Scholar
• Cutter NC, Scott DD, Johnson JC, Whiteneck G. Gabapentin effect on spasticity in multiple sclerosis: A placebo-controlled, randomized trial. Archives of Physical Medicine and Rehabilitation 2000; 81: 164–169
   PubMed Web of Science ®Google Scholar
• Priebe MM, Sherwood AM, Graves DE, Mueller M, Olson WH. Effectiveness of gabapentin in controlling spasticity: A quantitative study. Spinal Cord 1997; 35: 171–175
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Chronic Conditions. Multiple sclerosis, national clinical guideline for diagnosis and management in primary and secondary care. London: National Collaborating Centre for Chronic Conditions; 2004. Available online at: http://www.rcplondon.ac.uk/pubs/contents/409ed7a2-ae44-472f-ba3b-ab7164229493.pdf p102, accessed May 2011
   Google Scholar
• Shneker BF, McAuley JW. Pregabalin: A new neuromodulator with broad therapeutic indications. Annals of Pharmacotherapy 2005; 39: 2029–2037
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: A double-blind, placebo-controlled trial. Pain 2004; 110: 628–638
   PubMed Web of Science ®Google Scholar
• French JA, Kugler AR, Robbins JL, Knapp LE, Garofalo EA. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 2003; 60: 1631–1637
   PubMed Web of Science ®Google Scholar
• Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, Londborg PD, Bielski RJ, Zimbroff DL, Davidson JRT, et al. Pregabalin in generalized anxiety disorder: A placebo-controlled trial. American Journal of Psychiatry 2003; 160: 533–540
   PubMed Web of Science ®Google Scholar
• Bradley LJ, Kirker SG. Pregabalin in the treatment of spasticity: A retrospective case series. Disability & Rehabilitation 2007; 11: 1–3
   Google Scholar
• Nottcutt W, Davies P, Langford R, Ratcliffe S. Results of a randomised withdrawal study of subjects with spasticity due to multiple sclerosis who were receiving longterm Sativex. Dusseldorf: 25th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) September. 2009
   Google Scholar
• Ambler Z, Davies P, Gasperini C, Haas J, Klimek A, Montalban X, A two-phase study of Sativex® in the relief of spasticity due to multiple sclerosis: Phase A single-blind response assessment followed by phase B double-blind, randomised, placebo-controlled, parallel-group study. Dusseldorf: 25th European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) September, 2009
   Google Scholar
• Montalban X, Wright S. Trial period for new symptomatic treatments: lessons learnt from a Sativex in MS spasticity clinical trial. Dusseldorf: 25th European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS). September. 2009
   Google Scholar
• Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964; 192: 540–542
   PubMedGoogle Scholar
• Hobart JC, Riazi A, Thompson AJ, Styles IM, Ingram W, Vickery PJ, Warner M, Fox PJ, Zajicek JP. Getting the measure of spasticity in multiple sclerosis: The Multiple Sclerosis Spasticity Scale (MSSS-88). Brain 2006; 129: 224–234
   PubMed Web of Science ®Google Scholar
• Stacey BR, Dworkin RH, Murphy K, Sharma U, Emir B, Griesing T. Pregabalin in the treatment of refractory neuropathic pain: Results of a 15-month open label trial. Pain Medicine 2008; 9: 1202–1208
   PubMed Web of Science ®Google Scholar